Jan. 17 , 2008 - Immunosyn Corporation (OTC Bulletin Board: IMYN ) announced that the first phase of a formal "Proof of Concept Trial" for the biopharmaceutical SF-1019 has been successfully completed in Europe for treatment of Diabetic Ulcers ... 
Argyll Biotechnologies is the developer and licensor of SF-1019, for which Immunosyn has been granted the world-wide rights to market, sell and distribute under an exclusive license agreement... [PDF] Immunosyn' s Press Release-
